Corbus Pharmaceuticals - CRBP Competitors

Corbus Pharmaceuticals (NASDAQ:CRBP) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

Does the MarketBeat Community believe in CRBP or LUMO?

Corbus Pharmaceuticals received 399 more outperform votes than Lumos Pharma when rated by MarketBeat users. However, 71.43% of users gave Lumos Pharma an outperform vote while only 68.72% of users gave Corbus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Corbus Pharmaceuticals	Outperform Votes 424 68.72%	Underperform Votes 193 31.28%
Lumos Pharma	Outperform Votes 25 71.43%	Underperform Votes 10 28.57%

Does the media prefer CRBP or LUMO?

In the previous week, Lumos Pharma had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 1 mentions for Lumos Pharma and 0 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.98 beat Lumos Pharma's score of 0.76 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Positive
Lumos Pharma	Positive

Which has better earnings and valuation, CRBP or LUMO?

Lumos Pharma has higher revenue and earnings than Corbus Pharmaceuticals. Lumos Pharma is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	$880 thousand	31.56	-$42.35 million	-$10.42	-0.64
Lumos Pharma	$1.52 million	18.06	-$31.06 million	-$3.70	-0.90

Do analysts rate CRBP or LUMO?

Corbus Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential downside of 54.95%. Lumos Pharma has a consensus target price of $17.67, suggesting a potential upside of 428.94%. Given Lumos Pharma's higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lumos Pharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Is CRBP or LUMO more profitable?

Corbus Pharmaceuticals has a net margin of 0.00% compared to Lumos Pharma's net margin of -2,039.53%. Lumos Pharma's return on equity of -43.80% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-80.51%	-46.99%
Lumos Pharma	-2,039.53%	-43.80%	-37.63%

Do insiders & institutionals believe in CRBP or LUMO?

18.7% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Lumos Pharma shares are held by institutional investors. 6.3% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more volatility & risk, CRBP or LUMO?

Corbus Pharmaceuticals has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Summary

Lumos Pharma beats Corbus Pharmaceuticals on 11 of the 18 factors compared between the two stocks.